At the time of writing, Qiagen NV [QGEN] stock is trading at $44.53, up 1.23%. An important factor to consider is whether the stock is rising or falling in short-term value. The QGEN shares have gain 4.07% over the last week, with a monthly amount drifted -0.60%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 27, February 2024, QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery. In a post published today on Yahoo Finance, QIAGEN Biomedical KB-AI contains over 640 million biomedical relationships, including gene, disease and drug causal relationships, to aid in data-driven drug discovery // AI-driven insights complement human-curated QIAGEN Biomedical KB-HD and help identify novel relationships between diseases, biological pathways and molecular interactions that may be missed by traditional methods // Workflow cuts down on hypothesis testing time and speeds up the identification of promising therapeutic avenues with clear, structured data.
From an analyst’s perspective:
Qiagen NV [NYSE: QGEN] stock has seen the most recent analyst activity on December 19, 2023, when Wells Fargo initiated its Equal Weight rating and assigned the stock a price target of $44. On December 07, 2023, upgrade upgraded it’s rating to Buy but maintained its price target of $50 on the stock. Robert W. Baird started tracking the stock assigning a Outperform rating and suggested a price target of $50 on September 12, 2023. Morgan Stanley upgraded its rating to a Overweight. In a note dated January 18, 2022, DZ Bank upgraded an Buy rating on this stock.
For the past year, the stock price of Qiagen NV fluctuated between $34.74 and $47.69. Currently, Wall Street analysts expect the stock to reach $54.56 within the next 12 months. Qiagen NV [NYSE: QGEN] shares were valued at $44.53 at the most recent close of the market. An investor can expect a potential return of 22.52% based on the average QGEN price forecast.
Analyzing the QGEN fundamentals
According to Qiagen NV [NYSE:QGEN], the company’s sales were 1.97B for trailing twelve months, which represents an 2.24% jump. Gross Profit Margin for this corporation currently stands at 0.64% with Operating Profit Margin at 0.24%, Pretax Profit Margin comes in at 0.22%, and Net Profit Margin reading is 0.17%. To continue investigating profitability, this company’s Return on Assets is posted at 0.06, Equity is 0.09 and Total Capital is 0.09. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.4.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 44.26 points at the first support level, and at 43.98 for the second support level. However, for the 1st resistance point, the stock is sitting at 44.73, and for the 2nd resistance point, it is at 44.92.
Qiagen NV [QGEN] reported earnings per share of $0.55 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of $0.55/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.51 per share as compared to estimates of $0.5 per share, a difference of $0.01 representing a surprise of 2.00%.
Ratios To Look Out For
It is important to note that Qiagen NV [NYSE:QGEN] has a current ratio of 1.99. On the other hand, the Quick Ratio is 1.62, and the Cash Ratio is 0.62. Considering the valuation of this stock, the price to sales ratio is 5.02, the price to book ratio is 2.59 and price to earnings (TTM) ratio is 29.19.
